{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:11:17Z","timestamp":1790885477152,"version":"4.1.0"},"reference-count":29,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.1620\/tjem.2025.j088","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T18:09:35Z","timestamp":1751479775000},"page":"167-178","source":"Crossref","is-referenced-by-count":1,"title":["Elevated Expression of EphA10 in Gastric Cancer Tissues: A Potential Biomarker for Tumor Metastasis and Poor Survival"],"prefix":"10.1620","volume":"269","author":[{"given":"Dongni","family":"Leng","sequence":"first","affiliation":[{"name":"Department of Pathology, Nanjing JunXie Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjie","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing JunXie Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiya","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing JunXie Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing JunXie Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, the Affiliated Jinling Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hygiene and Logistics, Nanjing JunXie Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"Cha, J.H., Chan, L.C., Wang, Y.N., Chu, Y.Y., Wang, C.H., Lee, H.H., Xia, W., Shyu, W.C., Liu, S.P., Yao, J., Chang, C.W., Cheng, F.R., Liu, J., Lim, S.O., Hsu, J.L., et al. (2022)  Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. <i>J. Biol. Chem.<\/i>, 298, 101817. https:\/\/doi.org\/10.1016\/j.jbc.2022.101817","DOI":"10.1016\/j.jbc.2022.101817"},{"key":"2","doi-asserted-by":"publisher","unstructured":"Chen, M., Wang, G., Xu, Z., Sun, J., Liu, B., Chang, L., Gu, J., Ruan, Y., Gao, X.&amp;Song, S. (2024)  Loss of RACK1 promotes glutamine addiction via activating AKT\/mTOR\/ASCT2 axis to facilitate tumor growth in gastric cancer. <i>Cell. Oncol.<\/i> (<i>Dordr.<\/i>), 47, 113-128. https:\/\/doi.org\/10.1007\/s13402-023-00854-1","DOI":"10.1007\/s13402-023-00854-1"},{"key":"3","doi-asserted-by":"publisher","unstructured":"Guo, X., Yang, Y., Tang, J.&amp;Xiang, J. (2024)  Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity. <i>Cell Commun. Signal.<\/i>, 22, 299. https:\/\/doi.org\/10.1186\/s12964-024-01580-3","DOI":"10.1186\/s12964-024-01580-3"},{"key":"4","doi-asserted-by":"publisher","unstructured":"Hong, H.N., Won, Y.J., Shim, J.H., Kim, H.J., Han, S.H., Kim, B.S.&amp;Kim, H.S. (2018)  Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner. <i>J. Cancer Res. Clin. Oncol.<\/i>, 144, 1649-1663. https:\/\/doi.org\/10.1007\/s00432-018-2683-8","DOI":"10.1007\/s00432-018-2683-8"},{"key":"5","doi-asserted-by":"publisher","unstructured":"Inokuchi, M., Nakagawa, M., Baogok, N., Takagi, Y., Tanioka, T., Gokita, K., Okuno, K.&amp;Kojima, K. (2018)  Prognostic Significance of High EphA1-4 Expression Levels in Locally Advanced Gastric Cancer. <i>Anticancer Res.<\/i>, 38, 1685-1693. https:\/\/doi.org\/10.21873\/anticanres.12402","DOI":"10.21873\/anticanres.12402"},{"key":"6","doi-asserted-by":"publisher","unstructured":"Jukonen, J., Moyano-Galceran, L., Hopfner, K., Pietila, E.A., Lehtinen, L., Huhtinen, K., Gucciardo, E., Hynninen, J., Hietanen, S., Grenman, S., Ojala, P.M., Carpen, O.&amp;Lehti, K. (2021)  Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality. <i>Sci. Rep.<\/i>, 11, 8856. https:\/\/doi.org\/10.1038\/s41598-021-88382-6","DOI":"10.1038\/s41598-021-88382-6"},{"key":"7","doi-asserted-by":"publisher","unstructured":"Li, Y., Jin, L., Ye, F., Ma, Q., Yang, Z., Liu, D., Yang, J., Ma, D.&amp;Gao, Q. (2017)  Isoform expression patterns of EPHA10 protein mediate breast cancer progression by regulating the E-Cadherin and beta-catenin complex. <i>Oncotarget<\/i>, 8, 30344-30356. https:\/\/doi.org\/10.18632\/oncotarget.15910","DOI":"10.18632\/oncotarget.15910"},{"key":"8","doi-asserted-by":"publisher","unstructured":"Li, Y., Peng, Q.&amp;Wang, L. (2023)  EphA2 as a phase separation protein associated with ferroptosis and immune cell infiltration in colorectal cancer. <i>Aging<\/i> (<i>Albany N.Y.<\/i>), 15, 12952-12965. https:\/\/doi.org\/10.18632\/aging.205212","DOI":"10.18632\/aging.205212"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Lin, J.L., Lin, J.X., Lin, G.T., Huang, C.M., Zheng, C.H., Xie, J.W., Wang, J.B., Lu, J., Chen, Q.Y.&amp;Li, P. (2024)  Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. <i>BMC Public Health<\/i>, 24, 1763. https:\/\/doi.org\/10.1186\/s12889-024-19104-6","DOI":"10.1186\/s12889-024-19104-6"},{"key":"10","doi-asserted-by":"publisher","unstructured":"Nagano, K., Kanasaki, S., Yamashita, T., Maeda, Y., Inoue, M., Higashisaka, K., Yoshioka, Y., Abe, Y., Mukai, Y., Kamada, H., Tsutsumi, Y.&amp;Tsunoda, S. (2013)  Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. <i>Cancer Med.<\/i>, 2, 972-977. https:\/\/doi.org\/10.1002\/cam4.156","DOI":"10.1002\/cam4.156"},{"key":"11","doi-asserted-by":"publisher","unstructured":"Nagano, K., Yamashita, T., Inoue, M., Higashisaka, K., Yoshioka, Y., Abe, Y., Mukai, Y., Kamada, H., Tsutsumi, Y.&amp;Tsunoda, S. (2014)  Eph receptor A10 has a potential as a target for a prostate cancer therapy. <i>Biochem. Biophys. Res. Commun.<\/i>, 450, 545-549. https:\/\/doi.org\/10.1016\/j.bbrc.2014.06.007","DOI":"10.1016\/j.bbrc.2014.06.007"},{"key":"12","doi-asserted-by":"publisher","unstructured":"Nasri, B., Inokuchi, M., Ishikawa, T., Uetake, H., Takagi, Y., Otsuki, S., Kojima, K.&amp;Kawano, T. (2017)  High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival. <i>BMC Clin. Pathol.<\/i>, 17, 8. https:\/\/doi.org\/10.1186\/s12907-017-0047-y","DOI":"10.1186\/s12907-017-0047-y"},{"key":"13","unstructured":"Nie, Y., Zhao, W., Lu, L.&amp;Zhou, F. (2023)  Predictive biomarkers and new developments of immunotherapy in gastric cancer: a 2023 update. <i>Am. J. Cancer Res.<\/i>, 13, 3169-3184."},{"key":"14","doi-asserted-by":"crossref","unstructured":"Pasquale, E.B.(2024)  Eph receptors and ephrins in cancer progression. <i>Nat. Rev. Cancer<\/i>, 24, 5-27. https:\/\/doi.org\/10.1038\/s41568-023-00634-x","DOI":"10.1038\/s41568-023-00634-x"},{"key":"15","doi-asserted-by":"publisher","unstructured":"Scarini, J.F., Goncalves, M.W.A., de Lima-Souza, R.A., Lavareze, L., de Carvalho Kimura, T., Yang, C.C., Altemani, A., Mariano, F.V., Soares, H.P., Fillmore, G.C.&amp;Egal, E.S.A. (2024)  Potential role of the Eph\/ephrin system in colorectal cancer: emerging druggable molecular targets. <i>Front. Oncol.<\/i>, 14, 1275330. https:\/\/doi.org\/10.3389\/fonc.2024.1275330","DOI":"10.3389\/fonc.2024.1275330"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Shin, W.S., Park, M.K., Lee, Y.H., Kim, K.W., Lee, H.&amp;Lee, S.T. (2020)  The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells. <i>Cancer Sci.<\/i>, 111, 3292-3302. https:\/\/doi.org\/10.1111\/cas.14568","DOI":"10.1111\/cas.14568"},{"key":"17","doi-asserted-by":"publisher","unstructured":"Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A.&amp;Bray, F. (2021)  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>CA Cancer J. Clin.<\/i>, 71, 209-249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Talia, M., Cirillo, F., Spinelli, A., Zicarelli, A., Scordamaglia, D., Muglia, L., De Rosis, S., Rigiracciolo, D.C., Filippelli, G., Perrotta, I.D., Davoli, M., De Rosa, R., Macirella, R., Brunelli, E., Miglietta, A.M., et al. (2023)  The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. <i>J. Exp. Clin. Cancer Res.<\/i>, 42, 164. https:\/\/doi.org\/10.1186\/s13046-023-02747-5","DOI":"10.1186\/s13046-023-02747-5"},{"key":"19","doi-asserted-by":"publisher","unstructured":"Tomiyama, E., Fujita, K., Matsuzaki, K., Narumi, R., Yamamoto, A., Uemura, T., Yamamichi, G., Koh, Y., Matsushita, M., Hayashi, Y., Hashimoto, M., Banno, E., Kato, T., Hatano, K., Kawashima, A., et al. (2022)  EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer. <i>Br. J. Cancer<\/i>, 127, 1312-1323. https:\/\/doi.org\/10.1038\/s41416-022-01860-0","DOI":"10.1038\/s41416-022-01860-0"},{"key":"20","doi-asserted-by":"publisher","unstructured":"Veiga, R.N., de Azevedo, A.L.K., de Oliveira, J.C.&amp;Gradia, D.F. (2024)  Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer. <i>J. Mol. Med. <\/i>(<i>Berl.<\/i>), 102, 479-493. https:\/\/doi.org\/10.1007\/s00109-024-02431-x","DOI":"10.1007\/s00109-024-02431-x"},{"key":"21","doi-asserted-by":"publisher","unstructured":"Wang, A., Zhu, J., Li, Y., Jiao, M., Zhang, S., Ding, Z.L., Huang, J.A.&amp;Liu, Z. (2024)  Comprehensive analysis of Epha10 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in non-small cell lung cancer. <i>Sci. Rep.<\/i>, 14, 19623. https:\/\/doi.org\/10.1038\/s41598-024-70466-8","DOI":"10.1038\/s41598-024-70466-8"},{"key":"22","unstructured":"Yan, H.X., Li, Q.L., Cai, W.W., Tang, D., Wang, B., Liu, X., Liu, Z.D.&amp;Yang, Z.L. (2018)  EphA10 and EphB3 are prognostic markers in gallbladder squamous cell\/adenosquamous carcinomas and adenocarcinomas. <i>Int. J. Clin. Exp. Pathol.<\/i>, 11, 512-525."},{"key":"23","doi-asserted-by":"publisher","unstructured":"Ying, J., Xu, Q., Liu, B., Zhang, G., Chen, L.&amp;Pan, H. (2015)  The expression of the PI3K\/AKT\/mTOR pathway in gastric cancer and its role in gastric cancer prognosis. <i>Onco Targets Ther.<\/i>, 8, 2427-2433. https:\/\/doi.org\/10.2147\/OTT.S88592","DOI":"10.2147\/OTT.S88592"},{"key":"24","doi-asserted-by":"publisher","unstructured":"Zhang, G., Song, J., Feng, Z., Zhao, W., Huang, P., Liu, L., Zhang, Y., Su, X., Wu, Y., Cao, Y., Li, Z.&amp;Jie, Z. (2022)  Artificial intelligence applicated in gastric cancer: A bibliometric and visual analysis via CiteSpace. <i>Front. Oncol.<\/i>, 12, 1075974. https:\/\/doi.org\/10.3389\/fonc.2022.1075974","DOI":"10.3389\/fonc.2022.1075974"},{"key":"25","doi-asserted-by":"publisher","unstructured":"Zhang, W., Wei, X., Guo, S., Wang, J., Liu, J.&amp;Wang, H. (2019)  Differential expression of EphA5 protein in gastric carcinoma and its clinical significance. <i>Oncol. Lett.<\/i>, 17, 5147-5153. https:\/\/doi.org\/10.3892\/ol.2019.10167","DOI":"10.3892\/ol.2019.10167"},{"key":"26","doi-asserted-by":"publisher","unstructured":"Zhao, P., Jiang, D., Huang, Y.&amp;Chen, C. (2021)  EphA2: A promising therapeutic target in breast cancer. <i>J. Genet. Genomics<\/i>, 48, 261-267. https:\/\/doi.org\/10.1016\/j.jgg.2021.02.011","DOI":"10.1016\/j.jgg.2021.02.011"},{"key":"27","doi-asserted-by":"publisher","unstructured":"Zhao, W., Liu, L., Li, X.&amp;Xu, S. (2022)  EphA10 drives tumor progression and immune evasion by regulating the MAPK\/ERK cascade in lung adenocarcinoma. <i>Int. Immunopharmacol.<\/i>, 110, 109031. https:\/\/doi.org\/10.1016\/j.intimp.2022.109031","DOI":"10.1016\/j.intimp.2022.109031"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Zheng, C.H., Wang, J.B., Lin, M.Q., Zhang, P.Y., Liu, L.C., Lin, J.X., Lu, J., Chen, Q.Y., Cao, L.L., Lin, M., Tu, R.H., Xie, J.W., Li, P.&amp;Huang, C.M. (2018)  CDK5RAP3 suppresses Wnt\/beta-catenin signaling by inhibiting AKT phosphorylation in gastric cancer. <i>J. Exp. Clin. Cancer Res.<\/i>, 37, 59. https:\/\/doi.org\/10.1186\/s13046-018-0716-4","DOI":"10.1186\/s13046-018-0716-4"},{"key":"29","doi-asserted-by":"publisher","unstructured":"Zhu, Y., Lu, Y., Zhu, Y., Ren, X., Deng, Q., Yang, M.&amp;Liang, X. (2024)  ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6\/PI3K\/Akt\/NF-kappaB pathway via IL-33. <i>Sci. Rep.<\/i>, 14, 26393. https:\/\/doi.org\/10.1038\/s41598-024-76763-6","DOI":"10.1038\/s41598-024-76763-6"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/2\/269_2025.J088\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:29:27Z","timestamp":1783744167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/2\/269_2025.J088\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2025.j088","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2025.J088"}}